Genmab and Incyte to test KRAS G12D combination in colorectal cancer
Genmab will run a Phase 1/2 study pairing petosemtamab with Incyte's INCB161734 and chemotherapy as first-line treatment for metastatic colorectal cancer.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Genmab will run a Phase 1/2 study that combines petosemtamab with Incyte's KRAS G12D inhibitor INCB161734 and standard chemotherapy. The trial targets first-line treatment of metastatic colorectal cancer with a KRAS G12D mutation. Incyte will co-fund the study and supply its drug. Both companies described the deal in press releases distributed by BusinessWire, and the details were reported by TradingView.
why it matters
This is an early-stage program, and no immediate effect on financial results is expected. For the shares to move meaningfully, the companies will need first safety and efficacy data and clear enrollment timelines. Shared funding lowers each partner's costs and shows that both are willing to split the risk of developing the program.
tags
instruments
sources
- Genmab A/S (GMAB) Partners With Incyte on KRAS G12D mCRC Trial — TradingView, 24 October 2026 at 11:01 UTC
- Incyte (INCY) Collaborates With Genmab on KRAS G12D mCRC Trial — TradingView, 24 October 2026 at 11:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗